Open Access

Neutrophil-to-Lymphocyte Ratio Predicts Immune-related Adverse Events in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

AKIFUMI KUWANO 1
MASAYOSHI YADA 1
KOSUKE TANAKA 1
YUTA KOGA 1
SHIGEHIRO NAGASAWA 1
AKIHIDE MASUMOTO 1
  &  
KENTA MOTOMURA 1

1Department of Hepatology, Aso Iizuka Hospital, Fukuoka, Japan

Cancer Diagnosis & Prognosis Jan-Feb; 4(1): 34-41 DOI: 10.21873/cdp.10282
Received 29 September 2023 | Revised 10 December 2024 | Accepted 06 November 2023
Corresponding author
Masayoshi Yada, MD, Ph.D., Department of Hepatology, Aso Iizuka Hospital, 3-83 Yoshio-machi, Iizuka, Fukuoka 820-8505, Japan. Tel: +81 948223800, Fax: +81 948295744, email: myadah1@aih-net.com
pdf image icon

Abstract

Background/Aim: Atezolizumab in combination with bevacizumab is an approved systemic chemotherapy regimen for advanced hepatocellular carcinoma (HCC). However, immune checkpoint inhibitors (ICIs), such as atezolizumab, frequently lead to immune-related adverse events (irAEs). The identification of biomarkers that can predict the occurrence of irAEs is crucial for the optimal management of patients undergoing ICI treatment. Patients and Methods: Between October 2020 and June 2023, we conducted a study involving 69 patients with advanced HCC who received treatment with atezolizumab plus bevacizumab. We conducted an analysis of blood-based biomarkers to identify independent risk factors associated with irAEs. Results: In our study, 12 out of 69 patients (17.4%) experienced irAEs. Our investigation into blood-based biomarkers revealed that a neutrophil–to-lymphocyte ratio (NLR) <2.04 at three weeks after the initiation of treatment had high predictive power (area under the curve: 0.77) for irAEs. Furthermore, multivariate logistic analysis identified NLR at three weeks (hazard ratio=0.23; p=0.037) and non-viral infection (hazard ratio=4.47; p=0.037) as independent factors contributing to the occurrence of irAEs. Patients who developed irAEs demonstrated a more favorable overall response rate (75.0% vs. 28.1%, p=0.005), disease control rate (91.6% vs. 52.6%, p=0.016), and progression-free survival (12.1 months vs. 6.0 months, p=0.010) than those who did not experience irAEs. Conclusion: An NLR <2.04 at three weeks after the initiation of treatment may serve as a valuable biomarker for predicting irAEs in patients with HCC undergoing atezolizumab plus bevacizumab therapy.
Keywords: hepatocellular carcinoma, atezolizumab plus bevacizumab, Neutrophil-to-lymphocyte ratio, immune-related adverse events

Hepatocellular carcinoma (HCC) is the sixth most prevalent neoplasm and causes the third most cancer-related fatalities globally, accounting for an estimated 900,000 new cases and 830,000 deaths in 2020 (1,2). Recent advancements in systemic chemotherapy for advanced HCC, including the development of immune checkpoint inhibitors (ICIs) and molecular targeted agents, have markedly enhanced patient outcomes (3-7).

The IMbrave150 study demonstrated the efficacy of atezolizumab plus bevacizumab, monoclonal antibodies targeting programmed death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF), respectively. This combination therapy led to extended progression-free survival (PFS) and overall survival (OS) in comparison to sorafenib for patients with advanced HCC (3). Consequently, atezolizumab plus bevacizumab is emerging as the primary systemic chemotherapy for advanced HCC.

ICIs stimulate an intensified T-cell-mediated response to facilitate the eradication of tumor cells. However, this heightened immune activity can also provoke a broad spectrum of adverse effects termed immune-related adverse events (irAEs). These irAEs can impact diverse organs, including the skin, gastrointestinal tract, liver, respiratory system, thyroid, and pituitary glands (8). The importance of irAEs is substantial as they are prevalent and often cause severe complications that can profoundly affect the quality of life and prognosis of patients undergoing ICI therapy. Moreover, finding the optimal approach to manage irAEs without compromising the antitumor response and long-term survival remains a challenge (9). Interestingly, patients experiencing irAEs tend to have a more favorable cancer-related prognosis (10-12). Thus, evaluating the individual risk of toxicity in advance is pivotal to guide the early management of irAEs. This proactive approach can enable the continued administration of ICIs to patients who are vulnerable to immune-mediated complications and, paradoxically, allow them to benefit more from treatment. As the use of ICIs continues to expand in the field of oncology, there is a growing need for dependable and validated biomarkers capable of predicting irAEs.

Regrettably, our understanding of predictive factors for irAEs in patients with HCC is limited. Therefore, we initiated an investigation to identify predictive factors for irAEs in patients with HCC undergoing treatment with atezolizumab plus bevacizumab.

Patients and Methods

Patients. In this single-center, prospective study conducted at the Aso Iizuka Hospital from December 2020 to June 2023, we enrolled patients with HCC who were administered atezolizumab plus bevacizumab. Of the 84 patients treated, 15 with a follow-up duration of less than 12 weeks were excluded, leaving 69 patients for evaluation. This study was conducted in accordance with the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Aso Iizuka Hospital (approval No. 22008). The opt-out method was used to obtain consent for this study.

Definition of irAEs. Adverse events perceived to have a possible immunological root, necessitating enhanced surveillance and potential intervention with immune suppressants or endocrine therapies, were categorized as irAEs. They were rated based on the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).

Biomarker analysis. The neutrophil–to-lymphocyte ratio (NLR) was determined by the quotient of the total neutrophils to total lymphocytes in peripheral blood, whereas the platelet-to-lymphocyte ratio (PLR) was ascertained by dividing the total platelets by the total lymphocytes.

Treatment protocol. Following the IMbrave150 trial protocol (3), patients were intravenously administered atezolizumab (1,200 mg) and bevacizumab (7.5 mg/kg) from Chugai (Tokyo, Japan) every three weeks. Treatment persisted until disease aggravation (PD) or the emergence of insufferable adverse events.

Evaluation of efficacy. Every 6 to 12 weeks following the start of treatment, computed tomography or magnetic resonance imaging were used to assess the treatment response. The antitumor response was gauged using modified RECIST version 1.1 (13). Indications of disease control rate (DCR) included complete response (CR), partial response (PR), and stable disease (SD) that persisted for a minimum of four months. The summation of PR and CR defined the objective response rate (ORR). Every three weeks, patients underwent evaluations and received treatment until either disease escalation (PD) or adverse reactions became intolerable.

Definitions of viral and non-viral infection. Patients with either anti-HCV antibody (Ab) or HBs-antigen (Ag) presence were classified as having a viral infection. Conversely, those negative for both serum anti-HCV Ab and HBs-Ag were categorized as having non-viral infections.

Statistical analysis. For all data processing, JMP Pro version 11 (SAS Institute, Cary, NC, USA) was used. The data are presented as median values with interquartile ranges. The Kaplan-Meier method, log-rank test, receiver operating characteristic (ROC) analysis, and Cox hazard analysis were the statistical tests applied. To determine predictive factors for irAE manifestation, ROC and area under the curve (AUC) values were computed. Differences in groups were assessed using the chi-squared test. All p-values were derived from two-tailed tests, and p<0.05 was considered to indicate a statistically significant difference.

Results

Patient characteristics. The characteristics of the 69 patients who received atezolizumab plus bevacizumab are shown in Table I. Twelve patients (17.4%) experienced grade >2 irAEs, which included five cases of adrenal insufficiency, two cases of interstitial pneumonia, two cases of tubulointerstitial nephritis, one case of enterocolitis, one case of stomatitis, and one case of immune thrombocytopenia. We classified the enrolled patients into those who experienced irAEs (irAE group) and those who did not (non-irAE group). The median age of the entire cohort was 73.0 (65.5-72.5) years old, and 82.6% of the patients were male. There were 12, 30, and 27 patients categorized as HBs-Ag, HCV Ab, and non-viral, respectively. In the irAE group, two patients had disease in Barcelona Clinic Liver Cancer (BCLC) stage A, four in BCLC stage B, and six in BCLC stage C. In the non-irAE group, one patient had disease in BCLC stage A, 26 in BCLC stage B, and 33 in BCLC stage C. Age, sex, body mass index, Child–Pugh grade, albumin-bilirubin score (ALBI) score, tumor size, number of intrahepatic lesions, microvascular invasion, extrahepatic spread, serum α-fetoprotein levels, protein induced by vitamin K absence or antagonist-II (known as PIVKA-II) levels, and NLR were similar between the two groups at the start of treatment. At three weeks after the start of treatment, patients in the irAE group had a lower NLR than those in the non-irAE group (p=0.019). There were more non-viral patients in the irAE group than in the non-irAE group (p=0.033).

Prognostic role of NLR for the development of irAEs. We determined the ROC values for the development of irAEs in the 69 patients based on multiple parameters, and set the cut-off values for the parameters (Table II). The cut-off value for NLR <2.04 at three weeks after the start of treatment was 2.04 (AUC=0.77).

Univariate logistic regression was performed to assess the risk factors for irAEs (Table III). Subsequent multivariate analysis revealed that NLR at three weeks (HR=0.23; p=0.037) and non-viral infection (HR=4.47; p=0.037) were independent factors that may contribute to irAE occurrence (Table III).

Efficacy of the association between irAEs and antitumor response. Among patients who received atezolizumab plus bevacizumab, the ORR (CR+PR) was 9/12 (75.0%) in the irAE group and 15/57 (28.1%) in the non-irAE group (p=0.005). The DCRs (CR+PR+SD) were 11/12 (91.6%) and 30/57 (52.6%) in the irAE and non-irAE groups, respectively (p=0.016) (Table IV). Therefore, there was a higher response rate among patients in the irAE group than in those in the non-irAE group following atezolizumab plus bevacizumab therapy.

Efficacy of the association between irAEs and PFS. The median PFS of all patients who received atezolizumab plus bevacizumab therapy was 6.8 months. Kaplan-Meier analysis revealed that the median PFS in the irAE group (12.1 months) was higher than that in the non-irAE group (6.0 months) (p=0.010) (Figure 1).

Discussion

In patients with advanced HCC, systemic therapy with a blend of ICI and VEGF inhibitors, notably atezolizumab and bevacizumab, is now endorsed (3). Therefore, it is imperative to evaluate irAE risks prior to treatment initiation. Recent research has focused on identifying predictive biomarkers for irAEs (14). The deployment of blood cell metrics for early irAE detection is gaining traction among medical professionals due to its accessibility, cost-efficiency, and straightforward interpretation. Current data, although not uniform, indicate that certain baseline blood cell counts and their increment during monitoring sessions correlate with increased irAE risks (15-34). Remarkably, no prior studies have delved into predictive determinants of irAEs within the HCC demographic. In our research, an NLR<2.04 at three weeks after the start of treatment manifested substantial predictive capability for patients with HCC undergoing atezolizumab and bevacizumab treatment.

The NLR is indicative of the cancer-induced inflammatory reaction and has correlations with patient outcomes and ICI treatment responsiveness across diverse cancer types (35-40). Persano et al. reported the prognositc index including NLR in HCC patients being treated with atezolizumab and bevacizumab (41). Eso et al. analyzed 40 patients with HCC receiving atezolizumab and bevacizumab and discovered significant NLR discrepancies between different response groups, with the most favorable responses showcasing the lowest NLR values (42). A concurrent multi-institutional study in Japan corroborated these findings, where survival outcomes varied markedly based on NLR levels (43). It has been reported that the NLR did not significantly worsen within 6 weeks after atezolizumab and bevacizumab initiation in HCC patients (44). In our study, Multivariate analysis demonstrated that NLR at three weeks was an independent predictor for OS (data not shown). In summary, NLR at three weeks was considered a vital predictor of irAEs and prognosis.

Recently, several studies have reported that irAEs were associated with the efficacy of ICI therapy in patients with HCC (45). Fukushima et al. reported that low-grade irAEs exhibited a strong association with better patient outcomes when treated with atezolizumab and bevacizumab (46). We observed that patients with irAEs had a better ORR and PFS compared to patients without irAEs. Although not statistically significant, OS tended to be longer in the irAE group compared to that in the non-irAE group (22.0 months vs. 16.2 months, p=0.10). This result can be attributed to the unmatched liver function at the start of chemotherapy due to the small number of cases.

Interestingly, our study revealed that liver etiology (non-viral) was another predictive marker associated with irAEs. Hatanaka et al. reported no significant differences in efficacy, and all treatment-related adverse events, including irAEs, were found between patients with non-viral infection and those with viral infections (47). There have been no previous reports on the association between irAEs and patients with non-viral liver etiology. Nucleoside analogs have been associated with significant improvement in liver inflammation and fibrosis in chronic HBV patients (48). Furthermore, direct-acting antivirals have been shown to reduce fibrosis in chronic HCV patients (49). In our study, most HBV and HCV patients were treated with these drugs, potentially leading to suppressed inflammation. Non-viral patients may have non-viral factors, such as alcohol consumption or obesity, which contribute to pre-existing inflammatory activity and susceptibility to an acute inflammatory response, further heightened by ICIs. More extensive studies are necessary to analyze the relationship between irAEs and liver etiology.

Limitations of this study include the small number of patients with HCC due to its single-center nature. Our results suggest that a lower NLR might enable a more efficient anti-tumor immune response, but also indicate a higher risk of immune-related toxicity.

Conclusion

An NLR <2.04 at three weeks after the start of treatment may be a biomarker for predicting irAEs in patients with HCC treated with atezolizumab plus bevacizumab therapy. Further studies are needed to predict and validate biomarkers for irAEs.

Conflicts of Interest

All Authors declare no competing interests in relation to this study.

Authors’ Contributions

A.K., M.Y., A.M., and K.M. designed the study. A.K., Y.K, S.N., K.T., and M.Y. assisted with the data analyses. A.K. wrote the initial draft of the manuscript. M.Y. contributed to the analysis and interpretation of the data. M.Y., A.M., and K.M. assisted in the preparation and critical review of the manuscript. All Authors approved the final version of the manuscript and agreed to be accountable for all aspects of the work.

Acknowledgements

The Authors are grateful to Y. Ishibashi for his assistance with manuscript preparation. The Authors thank Amanda Holland, Ph.D., from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript.

References

1 Caldwell S & Park SH The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol. 44(S19) 96 - 101 2009. DOI: 10.1007/s00535-008-2258-6
2 Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A & Bray F Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3) 209 - 249 2021. DOI: 10.3322/caac.21660
3 Finn RS Qin S Ikeda M Galle PR Ducreux M Kim T Kudo M Breder V Merle P Kaseb AO Li D Verret W Xu D Hernandez S Liu J Huang C Mulla S Wang Y Lim HY Zhu AX & Cheng A Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 382(20) 1894 - 1905 2020. DOI: 10.1056/NEJMoa1915745
4 Kudo M Finn RS Qin S Han KH Ikeda K Piscaglia F Baron A Park JW Han G Jassem J Blanc JF Vogel A Komov D Evans TRJ Lopez C Dutcus C Guo M Saito K Kraljevic S Tamai T Ren M & Cheng AL Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 391(10126) 1163 - 1173 2018. DOI: 10.1016/S0140-6736(18)30207-1
5 El-Khoueiry AB Sangro B Yau T Crocenzi TS Kudo M Hsu C Kim TY Choo SP Trojan J Welling TH Rd Meyer T Kang YK Yeo W Chopra A Anderson J Dela Cruz C Lang L Neely J Tang H Dastani HB & Melero I Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 389(10088) 2492 - 2502 2017. DOI: 10.1016/S0140-6736(17)31046-2
6 Zhu AX Finn RS Edeline J Cattan S Ogasawara S Palmer D Verslype C Zagonel V Fartoux L Vogel A Sarker D Verset G Chan SL Knox J Daniele B Webber AL Ebbinghaus SW Ma J Siegel AB Cheng AL Kudo M & KEYNOTE-224 investigators Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol. 19(7) 940 - 952 2018. DOI: 10.1016/S1470-2045(18)30351-6
7 Eso Y & Marusawa H Novel approaches for molecular targeted therapy against hepatocellular carcinoma. Hepatol Res. 48(8) 597 - 607 2018. DOI: 10.1111/hepr.13181
8 Postow MA Sidlow R & Hellmann MD Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 378(2) 158 - 168 2018. DOI: 10.1056/NEJMra1703481
9 Schneider BJ Naidoo J Santomasso BD Lacchetti C Adkins S Anadkat M Atkins MB Brassil KJ Caterino JM Chau I Davies MJ Ernstoff MS Fecher L Ghosh M Jaiyesimi I Mammen JS Naing A Nastoupil LJ Phillips T Porter LD Reichner CA Seigel C Song JM Spira A Suarez-Almazor M Swami U Thompson JA Vikas P Wang Y Weber JS Funchain P & Bollin K Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline update. J Clin Oncol. 39(36) 4073 - 4126 2021. DOI: 10.1200/JCO.21.01440
10 Petrelli F Grizzi G Ghidini M Ghidini A Ratti M Panni S Cabiddu M Ghilardi M Borgonovo K Parati MC Tomasello G Barni S Berruti A & Brighenti M Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother. 43(1) 1 - 7 2020. DOI: 10.1097/CJI.0000000000000300
11 Zhou X Yao Z Yang H Liang N Zhang X & Zhang F Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 18(1) 87 2020. DOI: 10.1186/s12916-020-01549-2
12 Park R Lopes L & Saeed A Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis. Clin Transl Oncol. 23(1) 100 - 109 2021. DOI: 10.1007/s12094-020-02397-5
13 Lencioni R & Llovet J Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 30(01) 052 - 060 2010. DOI: 10.1055/s-0030-1247132
14 Les I Martínez M Pérez-Francisco I Cabero M Teijeira L Arrazubi V Torrego N Campillo-Calatayud A Elejalde I Kochan G & Escors D Predictive biomarkers for checkpoint inhibitor immune-related adverse events. Cancers (Basel). 15(5) 1629 2023. DOI: 10.3390/cancers15051629
15 Diehl A Yarchoan M Hopkins A Jaffee E & Grossman SA Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors. Oncotarget. 8(69) 114268 - 114280 2017. DOI: 10.18632/oncotarget.23217
16 Nakamura Y Tanaka R Maruyama H Ishitsuka Y Okiyama N Watanabe R Fujimoto M & Fujisawa Y Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies. Jpn J Clin Oncol. 49(5) 431 - 437 2019. DOI: 10.1093/jjco/hyy201
17 Ma Y Ma X Wang J Wu S Wang J & Cao B Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis. World J Surg Oncol. 20(1) 242 2022. DOI: 10.1186/s12957-022-02695-y
18 Ruste V Goldschmidt V Laparra A Messayke S Danlos FX Romano-Martin P Champiat S Voisin AL Baldini C Massard C Laghouati S Marabelle A Lambotte O & Michot JM The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. Eur J Cancer. 158 217 - 224 2021. DOI: 10.1016/j.ejca.2021.08.048
19 Pavan A Calvetti L Dal Maso A Attili I Del Bianco P Pasello G Guarneri V Aprile G Conte P & Bonanno L Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Oncologist. 24(8) 1128 - 1136 2019. DOI: 10.1634/theoncologist.2018-0563
20 Eun Y Kim IY Sun JM Lee J Cha HS Koh EM Kim H & Lee J Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep. 9(1) 14039 2019. DOI: 10.1038/s41598-019-50574-6
21 Liu W Liu Y Ma F Sun B Wang Y Luo J Liu M & Luo Z Peripheral blood markers associated with immune-related adverse effects in patients who had advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Manag Res. 13 765 - 771 2021. DOI: 10.2147/CMAR.S293200
22 Bai R Chen N Chen X Li L Song W Li W Zhao Y Zhang Y Han F Lyu Z & Cui J Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events. Cancer Biol Med. 18(4) 1118 - 1133 2021. DOI: 10.20892/j.issn.2095-3941.2021.0052
23 Fujimoto A Toyokawa G Koutake Y Kimura S Kawamata Y Fukuishi K Yamazaki K & Takeo S Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer. 12(15) 2198 - 2204 2021. DOI: 10.1111/1759-7714.14063
24 Michailidou D Khaki AR Morelli MP Diamantopoulos L Singh N & Grivas P Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. Sci Rep. 11(1) 9029 2021. DOI: 10.1038/s41598-021-88307-3
25 Suazo-Zepeda E Bokern M Vinke PC Hiltermann TJN de Bock GH & Sidorenkov G Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Cancer Immunol Immunother. 70(11) 3069 - 3080 2021. DOI: 10.1007/s00262-021-02996-3
26 Egami S Kawazoe H Hashimoto H Uozumi R Arami T Sakiyama N Ohe Y Nakada H Aomori T Ikemura S Fukunaga K Yamaguchi M & Nakamura T Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: a multicenter retrospective study. J Cancer. 12(7) 2105 - 2112 2021. DOI: 10.7150/jca.53242
27 Xu H Feng H Zhang W Wei F Zhou L Liu L Zhao Y Lv Y Shi X Zhang J & Ren X Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence. Exp Cell Res. 416(1) 113157 2022. DOI: 10.1016/j.yexcr.2022.113157
28 Lee PY Oen KQX Lim GRS Hartono JL Muthiah M Huang DQ Teo FSW Li AY Mak A Chandran NS Tan CL Yang P Tai ES Ng KWP Vijayan J Chan YC Tan LL Lee MB Chua HR Hong WZ Yap ES Lim DK Yuen YS Chan YH Aminkeng F Wong ASC Huang Y & Tay SH Neutrophil-to-lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade: a case-control study. Cancers (Basel). 13(6) 1308 2021. DOI: 10.3390/cancers13061308
29 Chu X Zhao J Zhou J Zhou F Jiang T Jiang S Sun X You X Wu F Ren S Zhou C & Su C Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. Lung Cancer. 150 76 - 82 2020. DOI: 10.1016/j.lungcan.2020.08.015
30 Drobni ZD Zafar A Zubiri L Zlotoff DA Alvi RM Lee C Hartmann S Gilman HK Villani AC Nohria A Groarke JD Sullivan RJ Reynolds KL Zhang L & Neilan TG Decreased absolute lymphocyte count and increased neutrophil/lymphocyte ratio with immune checkpoint inhibitor-associated myocarditis. J Am Heart Assoc. 9(23) e018306 2020. DOI: 10.1161/JAHA.120.018306
31 Takada S Murooka H Tahatsu K Yanase M Umehara K Hashishita H Toru H Satoru M Sagawa T Fujikawa K Sato H & Mino K Identifying early predictive markers for immune-related adverse events in nivolumab-treated patients with renal cell carcinoma and gastric cancer. Asian Pac J Cancer Prev. 23(2) 695 - 701 2022. DOI: 10.31557/APJCP.2022.23.2.695
32 Fujisawa Y Yoshino K Otsuka A Funakoshi T Fujimura T Yamamoto Y Hata H Gosho M Tanaka R Yamaguchi K Nonomura Y Hirai I Furudate S Okuhira H Imafuku K Aoki M & Matsushita S Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab. J Dermatol Sci. 88(2) 225 - 231 2017. DOI: 10.1016/j.jdermsci.2017.07.007
33 Egami S Kawazoe H Hashimoto H Uozumi R Arami T Sakiyama N Ohe Y Nakada H Aomori T Ikemura S Fukunaga K Yamaguchi M & Nakamura T Absolute lymphocyte count predicts immune-related adverse events in patients with non-small-cell lung cancer treated with nivolumab monotherapy: a multicenter retrospective study. Front Oncol. 11 618570 2021. DOI: 10.3389/fonc.2021.618570
34 Zhang Z Xie T Qi C Zhang X Shen L & Peng Z Peripheral blood biomarkers predictive of efficacy outcome and immune-related adverse events in advanced gastrointestinal cancers treated with checkpoint inhibitors. Cancers (Basel). 14(15) 3736 2022. DOI: 10.3390/cancers14153736
35 Valero C Zanoni DK McGill MR Ganly I Morris LGT Quer M Shah JP Wong RJ León X & Patel SG Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer. Cancer. 126(5) 994 - 1003 2020. DOI: 10.1002/cncr.32591
36 Cedrés S Torrejon D Martínez A Martinez P Navarro A Zamora E Mulet-Margalef N & Felip E Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 14(11) 864 - 869 2012. DOI: 10.1007/s12094-012-0872-5
37 Azab B Bhatt VR Phookan J Murukutla S Kohn N Terjanian T & Widmann WD Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 19(1) 217 - 224 2012. DOI: 10.1245/s10434-011-1814-0
38 Guthrie GJ Charles KA Roxburgh CS Horgan PG McMillan DC & Clarke SJ The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit Rev Oncol Hematol. 88(1) 218 - 230 2013. DOI: 10.1016/j.critrevonc.2013.03.010
39 Stotz M Gerger A Eisner F Szkandera J Loibner H Ress AL Kornprat P AlZoughbi W Seggewies FS Lackner C Stojakovic T Samonigg H Hoefler G & Pichler M Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 109(2) 416 - 421 2013. DOI: 10.1038/bjc.2013.332
40 Walsh SR Cook EJ Goulder F Justin TA & Keeling NJ Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 91(3) 181 - 184 2005. DOI: 10.1002/jso.20329
41 Persano M Rimini M Tada T Suda G Shimose S Kudo M Cheon J Finkelmeier F Lim HY Presa J Masi G Yoo C Lonardi S Pressiani T Piscaglia F Kumada T Rimassa L Scartozzi M Cascinu S Casadei-Gardini A & HCC COLLABORATIVE GROUP Identification of atezolizumab plus bevacizumab prognostic index via recursive partitioning analysis in HCC: The ABE index. Anticancer Res. 43(4) 1599 - 1610 2023. DOI: 10.21873/anticanres.16310
42 Eso Y Takeda H Taura K Takai A Takahashi K & Seno H Pretreatment neutrophil-to-lymphocyte ratio as a predictive marker of response to atezolizumab plus bevacizumab for hepatocellular carcinoma. Curr Oncol. 28(5) 4157 - 4166 2021. DOI: 10.3390/curroncol28050352
43 Tada T Kumada T Hiraoka A Hirooka M Kariyama K Tani J Atsukawa M Takaguchi K Itobayashi E Fukunishi S Tsuji K Ishikawa T Tajiri K Ochi H Yasuda S Toyoda H Ogawa C Nishimura T Hatanaka T Kakizaki S Shimada N Kawata K Tanaka T Ohama H Nouso K Morishita A Tsutsui A Nagano T Itokawa N Okubo T Arai T Imai M Naganuma A Koizumi Y Nakamura S Joko K Iijima H Hiasa Y & Real-life Practice Experts for HCC (RELPEC) Study Group and the Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. Eur J Gastroenterol Hepatol. 34 698 - 706 2022. DOI: 10.1097/MEG.0000000000002356
44 Takeda S Namisaki T Tsuji Y Fujimoto Y Murata K Enomoto M Fujinaga Y Nishimura N Kitagawa K Takaya H Kaji K Inoue T Kawaratani H Akahane T Mitoro A & Yoshiji H Initial experience with atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma: a real-world retrospective study. Anticancer Res. 42(11) 5465 - 5473 2022. DOI: 10.21873/anticanres.16051
45 Ng KYY Tan SH Tan JJE Tay DSH Lee AWX Ang AJS Wong LWJ Choo SP Tai DW & Lee JJX Impact of immune-related adverse events on efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma. Liver Cancer. 11(1) 9 - 21 2021. DOI: 10.1159/000518619
46 Fukushima T Morimoto M Kobayashi S Ueno M Uojima H Hidaka H Kusano C Chuma M Numata K Tsuruya K Arase Y Kagawa T Hattori N Ikeda H Watanabe T Tanaka K & Maeda S Association between immune-related adverse events and survival in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Oncologist. 28(7) e526 - e533 2023. DOI: 10.1093/oncolo/oyad090
47 Hatanaka T Kakizaki S Hiraoka A Tada T Hirooka M Kariyama K Tani J Atsukawa M Takaguchi K Itobayashi E Fukunishi S Tsuji K Ishikawa T Tajiri K Ochi H Yasuda S Toyoda H Ogawa C Nishimura T Shimada N Kawata K Kosaka H Tanaka T Ohama H Nouso K Morishita A Tsutsui A Nagano T Itokawa N Okubo T Arai T Imai M Naganuma A Koizumi Y Nakamura S Joko K Kaibori M Iijima H Hiasa Y Kumada T & Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study. Cancer Med. 12(5) 5293 - 5303 2023. DOI: 10.1002/cam4.5337
48 Terrault NA Lok ASF McMahon BJ Chang KM Hwang JP Jonas MM Brown RS Jr Bzowej NH & Wong JB Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 67(4) 1560 - 1599 2018. DOI: 10.1002/hep.29800
49 Ferreira J Oliveira M Bicho M & Serejo F Role of inflammatory/immune response and cytokine polymorphisms in the severity of chronic hepatitis C (CHC) before and after direct acting antiviral (DAAs) treatment. Int J Mol Sci. 24(2) 1380 2023. DOI: 10.3390/ijms24021380